Individuals prescribed SGLT2 inhibitors had a greater proportion of current smokers and exhibited more pronounced metabolic abnormalities, including higher BMI, elevated fasting glucose levels, higher eGFR, and a higher prevalence of dyslipidemia compared to those not prescribed SGLT2 inhibitors. Here, SLC5A2 is linked to metabolic syndrome.